In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Francisco Sierra-LópezDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies, Av. IPN 2508, Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0002-4467-773X Susana Bernardo-HernándezHealth Research Unit, Hospital Regional de Alta Especialidad de Ixtapaluca, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Carr Mex-Puebla Km 34.5 col., Zoquiapan, Mexico City 56530, Mexico.ORCID 0009-0009-6027-0129 Lidia Baylón-PachecoDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies, Av. IPN 2508, Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0002-8405-8159 Verónica Ivonne Hernández-RamírezDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies, Av. IPN 2508, Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0002-1743-939X Vanessa Iglesias-VázquezHealth Research Unit, Hospital Regional de Alta Especialidad de Ixtapaluca, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Carr Mex-Puebla Km 34.5 col., Zoquiapan, Mexico City 56530, Mexico.
Rosa Martha Morales-LópezPathology Service, Hospital Regional de Alta Especialidad de Ixtapaluca, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Carr Mex-Puebla Km 34.5 col., Zoquiapan, Mexico City 56530, Mexico.
Juan Carlos Fernández HernándezHealth Research Unit, Hospital Regional de Alta Especialidad de Ixtapaluca, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Carr Mex-Puebla Km 34.5 col., Zoquiapan, Mexico City 56530, Mexico.
Gustavo Acosta AltamiranoHospital General de México "Dr. Eduardo Liceaga", Eje 2A Sur (Dr. Balmis) No. 148, Cuauhtémoc, Doctores, CDMX, Mexico City 06726, Mexico.
Patricia Talamás-RohanaDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies, Av. IPN 2508, Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0002-5085-814X José Luis Rosales-EncinaDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies, Av. IPN 2508, Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0002-5207-2909 Mónica Sierra-MartínezHealth Research Unit, Hospital Regional de Alta Especialidad de Ixtapaluca, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Carr Mex-Puebla Km 34.5 col., Zoquiapan, Mexico City 56530, Mexico.
Funding
Ministry of Sciences, Humanities, Technology and Innovation 104109Ministry of Sciences, Humanities, Technology and Innovation 104119Ministry of Sciences, Humanities, Technology and Innovation 362402
6 · The paper itselfAbstract
Histiocytic sarcoma (HS) is an aggressive hematological malignancy whose transformed cells exhibit morphological and immunophenotypic characteristics similar to macrophages, and arises de novo or as part of a clonal 'evolution' of other pre-existing hematological neoplasms. This study investigates the potential use of the J774A.1 cell line (a cell line derived from murine tumor cells, commonly used in macrophage research) as a research model to study the role of polydisperse extracellular vesicles (PEVs) secreted by the HS cells, considering that bacterial infections are common in patients with cancer, including HS. The influences of bacterial components on tumor progression are still not fully understood. We stimulated the J774A.1 cell line in vitro with a fraction of
Indexed as
Bacterial InfectionsCoinfectionExtracellular VesiclesHistiocytic SarcomaAnimalsCell Line, TumorEscherichia coliHumansMacrophagesMiceProteomicscancerextracellular vesicles (EVs)histiocytic sarcoma (HS)macrophagepolydisperse EVs (PEVs)
Identifiers
PMID42278472
PMCPMC13257283
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390